Table 3.

Adverse Events of Any Grade Occurring in ≥20% of Patients During the Treatment Period

	MTC (n = 8)		ATC (n = 10)		Total (N = 18)
Adverse events, n (%)	Any grade	Grade ≥3	Any grade	Grade ≥3	Any grade	Grade ≥3
Palmar-plantar erythrodysesthesia	8 (100)	4 (50)	5 (50)	0	13 (72)	4 (22)
Alopecia	7 (88)	0	3 (30)	0	10 (56)	0
Hypertension	5 (63)	1 (13)	5 (50)	2 (20)	10 (56)	3 (17)
Diarrhea	5 (63)	0	3 (30)	0	8 (44)	0
Stomatitis	5 (63)	0	2 (20)	0	7 (39)	0
Rash	2 (25)	0	4 (40)	0	6 (33)	0
Rash maculopapular	3 (38)	1 (13)	3 (30)	0	6 (33)	1 (6)
Blood TSH increased	3 (38)	0	3 (30)	0	6 (33)	0
ALT increased	3 (38)	2 (25)	2 (20)	1 (10)	5 (28)	3 (17)
Weight decreased	0	0	5 (50)	0	5 (28)	0
Headache	3 (38)	0	2 (20)	0	5 (28)	0
AST increased	2 (25)	2 (25)	2 (20)	2 (20)	4 (22)	4 (22)
Fatigue	1 (13)	0	3 (30)	0	4 (22)	0

TSH, thyrotropin.